Lipocine Inc (LPCN)
1.62
-0.03 -1.82%
NASDAQ
Jan 15, 20:00
USD
Lipocine Proceeds from Stock Option Exercised (Quarterly)
View 4,000+ financial data types
Browse...
View Full Chart
Proceeds from Stock Option Exercised (Quarterly) Chart
Historical Proceeds from Stock Option Exercised (Quarterly) Data
View and export this data going back to 2012.
Start your Free Trial
Export Data
Date Range:
Data for this Date Range | |
---|---|
Sept. 30, 2020 | Upgrade |
June 30, 2020 | Upgrade |
March 31, 2020 | Upgrade |
Dec. 31, 2019 | Upgrade |
Sept. 30, 2019 | Upgrade |
June 30, 2019 | Upgrade |
March 31, 2019 | Upgrade |
Dec. 31, 2018 | Upgrade |
Sept. 30, 2018 | Upgrade |
June 30, 2018 | Upgrade |
March 31, 2018 | Upgrade |
Dec. 31, 2017 | Upgrade |
Sept. 30, 2017 | Upgrade |
June 30, 2017 | Upgrade |
March 31, 2017 | Upgrade |
Dec. 31, 2016 | Upgrade |
Sept. 30, 2016 | Upgrade |
June 30, 2016 | Upgrade |
March 31, 2016 | Upgrade |
Dec. 31, 2015 | Upgrade |
Sept. 30, 2015 | Upgrade |
June 30, 2015 | Upgrade |
March 31, 2015 | Upgrade |
Dec. 31, 2014 | Upgrade |
Sept. 30, 2014 | Upgrade |
June 30, 2014 | Upgrade |
March 31, 2014 | Upgrade |
Dec. 31, 2013 | Upgrade |
Sept. 30, 2013 | Upgrade |
June 30, 2013 | Upgrade |
March 31, 2013 | Upgrade |
Dec. 31, 2012 | Upgrade |
Sept. 30, 2012 | Upgrade |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
View Proceeds from Stock Option Exercised (Quarterly) for LPCN
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Start your free 7-Day Trial.
Start My Free Trial
No credit card required.
Already a subscriber? Sign in.
Advertisement
Proceeds from Stock Option Exercised (Quarterly) Benchmarks
Infinity Pharmaceuticals Inc | Upgrade |
Cancer Genetics Inc | Upgrade |
Aldeyra Therapeutics Inc | Upgrade |
Proceeds from Stock Option Exercised (Quarterly) Range, Past 5 Years
Minimum | Upgrade | Jun 2016 |
Maximum | Upgrade | Jun 2020 |
Average | Upgrade |
News
Lipocine Says USPTO Grants Declaration of Interference, Withdraws Clarus Patent Application
MT Newswires 01/14 09:26 ET
MT Newswires 01/14 09:26 ET
Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
PR Newswire 01/14 08:00 ET
PR Newswire 01/14 08:00 ET
Lipocine Reports Positive Topline Results From Phase 2 Study of LPCN 1144 to Treat NASH; Shares Rise 7% Pre-Bell
MT Newswires 01/12 09:21 ET
MT Newswires 01/12 09:21 ET
Lipocine announces positive results from phase 2biopsy-confirmed NASH study
SA Breaking News 01/12 08:52 ET
SA Breaking News 01/12 08:52 ET
Lipocine to Start Extension Study to Test Safety of Liver Disease Drug Candidate
MT Newswires 12/30 11:03 ET
MT Newswires 12/30 11:03 ET
Lipocine's Jury Trial in Patent Lawsuit Against Clarus Therapeutics Postponed Due to COVID-19
MT Newswires 12/29 09:55 ET
MT Newswires 12/29 09:55 ET
Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics
PR Newswire 12/29 08:00 ET
PR Newswire 12/29 08:00 ET
--Analyst Actions: Ladenburg Thalmann Upgrades Lipocine to Buy From Neutral, $3 Price Target
MT Newswires 12/10 11:23 ET
MT Newswires 12/10 11:23 ET
Wall Street Sees Narrowly Mixed Open as Traders Monitor Vaccine, Stimulus News
MT Newswires 12/09 09:13 ET
MT Newswires 12/09 09:13 ET
Advertisement